Parry, Matthew G. http://orcid.org/0000-0002-9695-6052
Nossiter, Julie http://orcid.org/0000-0002-8597-7624
Morris, Melanie
Sujenthiran, Arunan
Skolarus, Ted A.
Berry, Brendan http://orcid.org/0000-0001-7132-5839
Nathan, Arjun http://orcid.org/0000-0002-8572-2832
Cathcart, Paul
Aggarwal, Ajay
van der Meulen, Jan http://orcid.org/0000-0002-9451-2335
Trinh, Quoc-Dien
Payne, Heather http://orcid.org/0000-0003-3238-5040
Clarke, Noel W.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA242559, R37 CA222885)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 5 October 2021
Revised: 24 November 2021
Accepted: 26 November 2021
First Online: 10 January 2022
Competing interests
: AS is an employee of Flatiron Health, an independent subsidiary of the Roche group, and holds stock in Roche. JvdM reports a contract with the Healthcare Quality Improvement Partnership for the provision of the National Prostate Cancer Audit (ExternalRef removed) funded by the Healthcare Quality Improvement Partnership (ExternalRef removed). HP has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Janssen, Sanofi Aventis, Takeda, Ipsen, Ferring, Sandoz, and Novartis. N.W.C. has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Bayer, Janssen, Sanofi Aventis, Takeda, Ipsen and Ferring.
: This study was exempt from NHS Research Ethics Committee approval because it involved analysis of pseudonymised linked data collated for the purpose of service evaluation as part of the National Prostate Cancer Audit.